By Mary Kohler ( February 13, 2025, 6:25 PM EST) -- Last year ushered in new Anti-Kickback Statute concerns for biopharma companies after Ultragenyx Pharmaceutical Inc. paid $6 million to settle U.S. Department of Justice allegations about its free genetic testing program in late 2023.[1] As the industry asked why, prosecutors warned of more to come.[2] At year-end, they delivered....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.